Louis DN (2016) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon.

Brat DJ, Aldape K, Colman H et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603–608

Article  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251

Article  CAS  PubMed  PubMed Central  Google Scholar 

Appay R, Dehais C, Maurage CA et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21:1519–1528

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang RR, Shi ZF, Zhang ZY et al (2020) IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathol 30:541–553

Article  CAS  PubMed  Google Scholar 

Shirahata M, Ono T, Stichel D et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166

Article  CAS  PubMed  Google Scholar 

Passon N, Pozzo F, Molinis C et al (2009) A simple multiplex real-time PCR methodology for the SMN1 gene copy number quantification. Genet Test Mol Biomarkers 13:37–42

Article  CAS  PubMed  Google Scholar 

Zhang X, Huang M, Wu X et al (2013) GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer. Pharmgenomics Pers Med 6:9–17

PubMed  PubMed Central  Google Scholar 

Satomi K, Ohno M, Matsushita Y et al (2021) Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod Pathol 34:688–700

Article  CAS  PubMed  Google Scholar 

Arita H, Narita Y, Matsushita Y et al (2015) Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol 32:22–30

Article  CAS  PubMed  Google Scholar 

Luchman HA, Stechishin OD, Dang NH et al (2012) An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 14:184–191

Article  CAS  PubMed  Google Scholar 

Setoodeh R, Schwartz S, Papenhausen P et al (2013) Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int J Clin Exp Pathol 6:155–167

PubMed  PubMed Central  Google Scholar 

Idbaih A, Ducray F, Dehais C et al (2013) SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS ONE. https://doi.org/10.1371/annotation/27807b78-9c79-414a-a47e-fb3eca621be4

Article  PubMed Central  Google Scholar 

Kamb A, Gruis NA, Weaver-Feldhaus J et al (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440

Article  CAS  PubMed  Google Scholar 

Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468

Article  CAS  PubMed  Google Scholar 

Reis GF, Pekmezci M, Hansen HM et al (2015) CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J Neuropathol Exp Neurol 74:442–452

Article  CAS  PubMed  Google Scholar 

Korshunov A, Casalini B, Chavez L et al (2019) Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathol Appl Neurobiol 45:108–118

Article  CAS  PubMed  Google Scholar 

Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77

Article  CAS  PubMed  Google Scholar 

Varn FS, Johnson KC, Martinek J et al (2022) Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 185:2184-2199.e16

Article  CAS  PubMed  Google Scholar 

Kocakavuk E, Anderson KJ, Varn FS et al (2021) Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nat Genet 53:1088–1096

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barthel FP, Johnson KC, Varn FS et al (2019) Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576:112–120

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt EE, Ichimura K, Reifenberger G, Collins VP (1994) CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321–6324

CAS  PubMed  Google Scholar 

Schmidt EE, Ichimura K, Messerle KR et al (1997) Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer 75:2–8

Article  CAS  PubMed  PubMed Central  Google Scholar